The Effect of Infliximab and Timing of Vaccination on the Humoral Response to Influenza Vaccination in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

References 

1. Gabriel SE, Crowson CS, Kremers NM, Doran MF, Turesson C, O'Fallozn WM, et al. Mortality in rheumatoid arthritis: have we made impacts in 4 decades?. Arthritis Rheum. 2003;48:54–58
   • MEDLINE
   • CrossRef
2. Symmons DP, Jones MA, Scott DL. Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol. 1998;25:1072–1077
   • MEDLINE
3. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum. 2002;46:2287–2293
   • MEDLINE
   • CrossRef
4. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285
   • CrossRef
5. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: Recommendation of the Advisory Committee on Immunization Practices (ACIP). National Center for Immunization and Respiratory Diseases (proposed). CDC July 28, 2006/55(RR10):1-42.
6. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65:191–194
   • MEDLINE
   • CrossRef
7. Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol. 1994;21:1203–1206
   • MEDLINE
8. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2007;46(4):608–611[Epub 2006 Nov 18].
   • MEDLINE
   • CrossRef
9. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324
   • MEDLINE
   • CrossRef
10. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368
    • MEDLINE
    • CrossRef
11. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–48
    • MEDLINE
    • CrossRef
12. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–2291
    • MEDLINE
13. Committee for Proprietary Medicinal Products (CPMC). Note for guidance on harmonization of requirements for influenza vaccines. CPMB/BWP/214/96, 1996, Circular No. 96-0666:1-22.
14. Committee for Proprietary Medicinal Products (CPMC). Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines, 2001, CPMP/EPW/1045/01.
15. Palmer DF, Coleman MT, Dowdle DC, Schild DC. Advanced laboratory techniques for influenza diagnosis (Public Health Service. US Department of Health, Education and Welfare). Atlanta (GA): Centers for Disease Control; 1975;
16. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumor necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2007 Oct 26;[Epub ahead of print].
17. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34(2):272–279
    • MEDLINE
18. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–660
    • CrossRef